Venmax Drugs & Pharmaceuticals Ltd Financials
Company Logo

Venmax Drugs & Pharmaceuticals Ltd Financial Statement

Venmax Drugs & Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue0.17
Operating Expense0.47
Net Profit-0.30
Net Profit Margin-176.47
Earning Per Share-0.58
EBIDTA-0.30
Effective Tax RateTBA

Venmax Drugs & Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue AnnualTBA
Operating Expenses Annual0.10
Operating Profit Annual0.09
Interest AnnualTBA
DepreciationTBA
Net Profit Annual0.06
Tax Annual0.02

Venmax Drugs & Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the BeginningTBA
Cash Flow from OperationsTBA
Cash Flow from InvestingTBA
Cash Flow from FinancingTBA
Cash Flow at the EndTBA

Venmax Drugs & Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)TBA
PBIT Margin (%)TBA
PBT Margin (%)TBA
Net PROFIT Margin (%)TBA
Return On Networth / Equity (%)1.15
Return On Networth /Employed (%)1.43
Return On Assets (%)TBA
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)TBA

Venmax Drugs & Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual0.07
Total Current Assets Annual0.02
Non Current Assets Annual0.07
Total Shareholders Funds Annual-0.65
Total Assets Annual0.08

Venmax Drugs & Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Jan 15, 2025, Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
Yes, Venmax Drugs & Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of -0.54.
In FY 2024 , Venmax Drugs & Pharmaceuticals Ltd recorded a total revenue of approximately 0 Cr marking a significant milestone in the company's financial performance.
Venmax Drugs & Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and NaN% annually, respectively..
Venmax Drugs & Pharmaceuticals Ltd's current PE ratio is undefined.
Venmax Drugs & Pharmaceuticals Ltd's ROCE averaged -134.6% from the FY ending March 2022 to 2024, with a median of -62.3%. It peaked at -29.2% in March 2024, reflecting strong capital efficiency over the period..
Venmax Drugs & Pharmaceuticals Ltd's latest EBIT is Rs. 0.09 Cr, surpassing the average EBIT of Rs. 0.72 Cr over the 5 years..

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions